Document Detail


KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy.
MedLine Citation:
PMID:  23208128     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: The prognostic and predictive value of KRAS mutations in patients with lung cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient studies, and biomarker status have led to inconsistent results in previous reports. METHODS: The KRAS and EGFR genes were examined in 1935 consecutive patients with non-small cell lung cancer. All patients were divided into KRAS mutation (KRAS group), EGFR mutation (EGFR group), and KRAS/EGFR wild type (WT group) groups. Randomly selected cases were paired with patients with the KRAS mutation, the EGFR mutation, and KRAS/EGFR wild type patients according to tumor, node, metastasis stage, time of first visit within 1 year, and pathology. Progression-free survival (PFS) and overall survival were evaluated by Kaplan-Meier and Cox models. RESULTS: The KRAS mutation rate for lung adenocarcinoma was 5.90 %. The overall survival was 14.47, 20.57, and 42.73 months for the KRAS group, WT group, and EGFR group, respectively (P < 0.001). Multivariate analysis indicated that KRAS mutation status was an independent prognostic factor (hazard ratio 2.69, 95 % confidence interval 1.91-3.80, P < 0.001). No difference was found in PFS and tumor responsiveness between patients with a KRAS mutation and those with wild type KRAS/EGFR for chemotherapy and EGFR tyrosine kinase inhibitors (TKI). PFS did not significantly differ for chemotherapy among the three groups (P = 0.270). CONCLUSIONS: KRAS mutation is a poor prognosis factor, but it is not an independent predictor of response to EGFR-TKI or chemotherapy in patients with lung cancer.
Authors:
Ji-Lin Guan; Wen-Zhao Zhong; She-Juan An; Jin-Ji Yang; Jian Su; Zhi-Hong Chen; Hong-Hong Yan; Zhi-Yong Chen; Zhi-Min Huang; Xu-Chao Zhang; Qiang Nie; Yi-Long Wu
Related Documents :
21755378 - A phase ii trial of neoadjuvant chemoradiation and local excision for t2n0 rectal cance...
25096608 - A simple technique to estimate best and worst case survival in patients with metastatic...
16707528 - Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode l...
23070108 - Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung ...
14528078 - Aerosolized granulocyte macrophage colony-stimulating factor (gm-csf) therapy in metast...
18051798 - Adrenalectomy for metastatic adrenal tumors.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-4
Journal Detail:
Title:  Annals of surgical oncology     Volume:  -     ISSN:  1534-4681     ISO Abbreviation:  Ann. Surg. Oncol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9420840     Medline TA:  Ann Surg Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  External Validation of Extranodal Extension and Lymph Node Density as Predictors of Survival in Node...
Next Document:  Factors Associated with Breast MRI Use: A Population-Based Analysis.